Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.4K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.2K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.2K
Pulmonary Function Tests01:25

Pulmonary Function Tests

1.0K
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
1.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).

Future oncology (London, England)·2026
Same author

Transposable element disruption of a second thyroglobulin-like gene confers Vip3Aa resistance in Helicoverpa armigera.

BMC genomics·2026
Same author

Quantitative Analysis of Bronchiectasis in Alpha-1 Antitrypsin Deficiency.

Canadian respiratory journal·2026
Same author

Association between mental health and chronic obstructive pulmonary disease (COPD) outcomes: systematic review and meta-analysis.

BMJ open respiratory research·2026
Same author

The Role of Alpha-1 Antitrypsin in the Pathophysiology and Treatment of Inflammatory Lung Diseases.

Journal of inflammation research·2026
Same author

Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.

Respiratory research·2026

Related Experiment Video

Updated: Apr 7, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.7K

Pulmonary Function Decline in Alpha-1 Antitrypsin Deficiency: A Systematic Review and Meta-Analysis.

Alice M Turner1, Priscilla Wittkopf2, Caroline von Wilamowitz-Moellendorff2

  • 1School of Health Sciences, University of Birmingham, Birmingham, UK.

International Journal of Chronic Obstructive Pulmonary Disease
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

This study estimates annual pulmonary function decline in alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Data are limited for AATD-associated liver disease, indicating an evidence gap for this patient group.

Keywords:
alpha-1 antitrypsin deficiencychronic obstructive pulmonary diseaseemphysemameta-analysisquality of liferespiratory function test

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.7K
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.3K

Area of Science:

  • Pulmonology
  • Genetics
  • Internal Medicine

Background:

  • Limited data exist on pulmonary function decline in alpha-1 antitrypsin deficiency (AATD)-associated lung and/or liver disease.
  • Pulmonary and liver manifestations of AATD significantly impact patient health and quality of life.

Purpose of the Study:

  • To conduct a systematic literature review (SLR) and meta-analysis on pulmonary function decline in AATD-associated lung and/or liver disease.
  • To identify associated risk factors, clinical outcomes, and health-related quality of life (HRQoL) changes.

Main Methods:

  • Systematic literature review (SLR) following PRISMA guidelines, including MEDLINE/Embase and congresses (2003-2023).
  • Two independent reviewers assessed study eligibility and quality using JBI tools.
  • Meta-analyses were performed on select outcomes, including forced expiratory volume in 1 second (FEV1) and St. George's Respiratory Questionnaire (SGRQ) scores.

Main Results:

  • 77 publications were included in the SLR; 32 reported on pulmonary function decline.
  • In AATD-associated lung disease, annualized FEV1 decline was -39.1 mL/year and -1.1 %/year, with a slight worsening in SGRQ score (1.3 points/year).
  • Data for AATD-associated liver disease (with or without lung disease) were insufficient for meta-analysis of pulmonary function or HRQoL decline.

Conclusions:

  • This SLR and meta-analysis provides an estimate of annual pulmonary function decline in AATD-associated lung disease.
  • An evidence gap exists regarding pulmonary function decline in AATD-associated liver disease.
  • Further research into risk factors and biomarkers is needed to optimize treatment strategies for AATD patients.